“Off-label” use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers
Alexandre O. Gérard, Serena Romani, Audrey Fresse, Delphine Viard, Nadège Parassol, Aurélie Granvuillemin, Laurent Chouchana, Fanny Rocher, Milou‐Daniel Drici
Topics & Concepts
PharmacovigilanceMedicineAzithromycinHydroxychloroquineLopinavirRitonavirQT intervalLopinavir/ritonavirAdverse effectChloroquineInternal medicinePharmacologyIntensive care medicineCoronavirus disease 2019 (COVID-19)VirologyMalariaDiseaseImmunologyAntibioticsBiologyViral loadInfectious disease (medical specialty)Antiretroviral therapyHuman immunodeficiency virus (HIV)MicrobiologyPharmacovigilance and Adverse Drug ReactionsCOVID-19 Clinical Research StudiesPharmacology and Obesity Treatment